AOD-9604 vs Semaglutide: Mechanism, Human Evidence, Cost, and Whether to Combine Them

Every figure is an all-in monthly price covering the medication, physician review, refill management and shipping. There is no separate membership fee. Semaglutide and tirzepatide are "from" prices because the vials are dose-specific and the price moves with the strength. Current pricing always lives on each product page.

No. This is the question behind most searches for the pair. Semaglutide activates the receptor for glucagon-like peptide-1, a gut hormone released after a meal, and its main effect in the weight trials runs through appetite. AOD-9604 acts on none of that. Nothing in its research describes an effect on hunger or fullness, it does not slow the stomach, and it does not lower blood sugar the way a GLP-1 does. The only thing the two have in common is that both are peptides and both are listed under weight loss. Peptides vs GLP-1 explains why "peptide" and "GLP-1" are not the same thing.

The real difference is evidence, not strength

People ask which is "stronger" for fat loss. That framing hides the important part. Semaglutide was tested in large trials for weight management and met its endpoints. AOD-9604 was also tested properly for weight, by the company that invented it, and did not separate from placebo. One is a weight-management medication with human evidence; the other is a peptide with an interesting animal mechanism and a negative human result for the very use it was designed for.

Semaglutide first

Semaglutide is the usual starting point when appetite and total body weight are the problem, within the BMI ranges its trials enrolled: 30 or more, or 27 or more with a weight-related condition. It has the longer track record of the two GLP-1s Pepti prescribes, the large cardiovascular outcomes trial and the lower starting price. If you are weighing it against tirzepatide, semaglutide vs tirzepatide covers that choice.

AOD-9604

AOD-9604 tends to come up for someone who is not a GLP-1 candidate on weight grounds, is already training and eating well, and wants a fat-metabolism signal that leaves appetite and the growth hormone axis alone. Prescribers typically frame it as support for a program that is already working, not as a driver of results on its own, and it suits people who understand that the human obesity trials were negative. It is also the AOD-9604 in the SHRED and PHYSIQ blends.

They act through unrelated mechanisms, and some prescribers do combine them. What is known and not known:

List everything you take on the intake. Your physician sets your directions for each product after reviewing it. What peptides can you take with tirzepatide covers the common pairings, and the same logic applies to semaglutide.

The two sit in completely different regulatory positions.

The 503B proposal concerns outsourcing facilities that compound in bulk; it does not by itself change the 503A pathway under which a pharmacy compounds for a named patient. Some sources claim AOD-9604 has FDA "GRAS" status; as of September 2026 there is no GRAS notice for it in the FDA's inventory, and it would have no bearing on a prescription injection anyway. Compounded medications are not FDA approved. Are peptides FDA approved explains the difference between not approved and not legal.

Both are injected under the skin (subcutaneously), rotating sites. The schedules and vials are different.

Semaglutide. Once weekly, the same day each week. Each strength is a separate dose-specific vial, so the volume changes with the strength: the starting vial holds 1 mg in 1 mL, drawn at 0.25 mL (25 units), and higher strengths use different concentrations and volumes. Treatment starts at the lowest strength and steps up, typically at roughly four-week intervals as tolerance allows. The semaglutide dosing chart shows every rung.

AOD-9604. 0.25 mL, which is 25 units on a U-100 insulin syringe, once daily Monday through Friday. From the 2 mg/mL vial that is 0.5 mg per dose. Some prescribers direct it in the morning before eating. Twenty doses cover about four weeks. AOD-9604 dosage goes through the conversion.

You do not need to calculate anything: your physician sets your directions after reviewing your intake, and your directions are printed on the vial. Both ship refrigerated with ice packs, with sterile syringes and alcohol prep pads, and refills run every 28 days, one vial per fill. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Semaglutide. Nausea, diarrhoea, vomiting, constipation and reduced appetite are the most common, mostly during dose increases and usually easing as the body adjusts. Less common but important: pancreatitis, gallbladder disease and dehydration. On insulin or a sulfonylurea, low blood sugar is possible. Slower gastric emptying can change how oral medications are absorbed. The approved labels carry a warning about thyroid C-cell tumours seen in rodents. Semaglutide side effects covers them in full.

AOD-9604. The six company trials give it more human safety data than most compounded peptides. Intravenous dosing was associated with headache, fatigue, dizziness and low blood sugar; oral dosing with headache, diarrhoea, flatulence, increased appetite and nausea, more so at the highest dose. Adverse events were similarly distributed between peptide and placebo. With the injection, prescribers mostly report injection-site redness, mild soreness or bruising. No human trial has used the subcutaneous route. AOD-9604 side effects has the detail.

For either, stop and contact your physician for any reaction that is severe, spreading or involves difficulty breathing, and for severe, persistent abdominal pain. For swelling of the face or throat or trouble breathing, call 911.

Semaglutide has one of the largest human evidence bases of any weight-management medicine, for the branded products those trials studied, run alongside diet and activity. Weight tends to return after it is stopped. AOD-9604 has a clean safety record from oral and intravenous trials, a negative result for weight loss, and nothing at all for the subcutaneous route that is prescribed. No trial has tested a compounded vial of either, and no trial has tested them together. Any provider presenting AOD-9604 as a "natural semaglutide" or as a trial-backed fat-burner is describing trials that reached the opposite conclusion. The wider picture is in best peptides for weight loss.

Neither can be bought legitimately without a prescription. Sites selling them "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A pharmacy compounds it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti is cash-pay and does not bill insurance. Step-by-step pages: how to get semaglutide prescribed online and how to get AOD-9604 prescribed online.